These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30730220)

  • 1. Abatacept for the treatment of rheumatoid arthritis.
    Pombo-Suarez M; Gomez-Reino JJ
    Expert Rev Clin Immunol; 2019 Apr; 15(4):319-326. PubMed ID: 30730220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of CTLA4-Ig on radiographic outcome of patients with rheumatoid arthritis].
    Harigai M
    Clin Calcium; 2007 Apr; 17(4):577-84. PubMed ID: 17404488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abatacept: A Review in Rheumatoid Arthritis.
    Blair HA; Deeks ED
    Drugs; 2017 Jul; 77(11):1221-1233. PubMed ID: 28608166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept.
    Laganà B; Vinciguerra M; D'Amelio R
    Clin Drug Investig; 2009; 29(3):185-202. PubMed ID: 19243211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
    Sherrer Y
    Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Abatacept].
    Nakamura T; Matsubara T
    Nihon Rinsho; 2013 Jul; 71(7):1232-7. PubMed ID: 23961672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CTLA4-Ig (abatacept)].
    Harigai M
    Nihon Rinsho; 2007 Jul; 65(7):1231-7. PubMed ID: 17642237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Abatacept].
    Iwamoto N; Kawakami A
    Nihon Rinsho; 2016 Jun; 74(6):968-73. PubMed ID: 27311187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting costimulatory activation of T cells : a viable treatment option for rheumatoid arthritis?
    Pollard LC
    Drugs; 2007; 67(1):1-9. PubMed ID: 17209660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents.
    Picchianti Diamanti A; Rosado MM; Scarsella M; Germano V; Giorda E; Cascioli S; Laganà B; D'Amelio R; Carsetti R
    Clin Exp Immunol; 2014 Sep; 177(3):630-40. PubMed ID: 24773026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
    Genovese MC; Pacheco-Tena C; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente RM; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Elegbe A; Wong R; Li X; Banerjee S; Alten R
    J Rheumatol; 2018 Aug; 45(8):1085-1092. PubMed ID: 29657147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis.
    Chitale S; Moots R
    Expert Opin Biol Ther; 2008 Jan; 8(1):115-22. PubMed ID: 18081541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders.
    Amano K; Matsubara T; Tanaka T; Inoue H; Iwahashi M; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T;
    Mod Rheumatol; 2015 Sep; 25(5):665-71. PubMed ID: 25698370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis.
    Teng GG; Turkiewicz AM; Moreland LW
    Expert Opin Biol Ther; 2005 Sep; 5(9):1245-54. PubMed ID: 16120053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Selective co-stimulation blockade. CTLA4-Ig (Abatacept)].
    Alten R; Märker-Hermann E
    Z Rheumatol; 2010 Sep; 69(7):601-7. PubMed ID: 20703487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice in the use of T cell co-stimulatory inhibitor for patients with rheumatoid arthritis.].
    Yasuda S
    Clin Calcium; 2018; 28(5):668-676. PubMed ID: 29731463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.
    Iwahashi M; Inoue H; Matsubara T; Tanaka T; Amano K; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T
    Mod Rheumatol; 2014 Nov; 24(6):885-91. PubMed ID: 24708204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
    Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
    Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How does abatacept really work in rheumatoid arthritis?
    Bonelli M; Scheinecker C
    Curr Opin Rheumatol; 2018 May; 30(3):295-300. PubMed ID: 29401118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis.
    D'Agostino MA; Alten R; Mysler E; Le Bars M; Ye J; Murthy B; Heitzmann J; Vadanici R; Ferraccioli G
    Clin Rheumatol; 2017 Dec; 36(12):2655-2665. PubMed ID: 28822046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.